DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,013,693 | +5.1% | 20,208 | +1.7% | 1.14% | +0.9% |
| Q2 2023 | $4,769,599 | -4.0% | 19,873 | +0.8% | 1.13% | -4.0% |
| Q1 2023 | $4,969,558 | -10.3% | 19,717 | -5.5% | 1.18% | -10.1% |
| Q4 2022 | $5,538,867 | +1.2% | 20,868 | -1.5% | 1.31% | -0.8% |
| Q3 2022 | $5,474,000 | +2.4% | 21,194 | +0.5% | 1.32% | +4.6% |
| Q2 2022 | $5,347,000 | -13.2% | 21,089 | +0.4% | 1.26% | +1.2% |
| Q1 2022 | $6,161,000 | -8.7% | 21,005 | +2.5% | 1.25% | -12.2% |
| Q4 2021 | $6,745,000 | +12.3% | 20,502 | +3.9% | 1.42% | +4.2% |
| Q3 2021 | $6,006,000 | +15.6% | 19,728 | +1.9% | 1.36% | +16.0% |
| Q2 2021 | $5,196,000 | +25.8% | 19,362 | +5.6% | 1.18% | +10.8% |
| Q1 2021 | $4,129,000 | +12.9% | 18,343 | +11.4% | 1.06% | +5.7% |
| Q4 2020 | $3,657,000 | +20.2% | 16,463 | +16.5% | 1.00% | +5.8% |
| Q3 2020 | $3,042,000 | +25.3% | 14,126 | +2.9% | 0.95% | +4.4% |
| Q2 2020 | $2,428,000 | +9.2% | 13,731 | +1.2% | 0.91% | -2.3% |
| Q1 2020 | $2,224,000 | +22.5% | 13,563 | +14.6% | 0.93% | +26.9% |
| Q4 2019 | $1,816,000 | +4.5% | 11,833 | -1.6% | 0.73% | -5.7% |
| Q3 2019 | $1,738,000 | -0.5% | 12,031 | -1.6% | 0.78% | -9.9% |
| Q2 2019 | $1,747,000 | +7.0% | 12,226 | -1.1% | 0.86% | -2.8% |
| Q1 2019 | $1,633,000 | +24.6% | 12,366 | -2.7% | 0.89% | +9.4% |
| Q4 2018 | $1,311,000 | -7.0% | 12,710 | -2.0% | 0.81% | +17.4% |
| Q3 2018 | $1,410,000 | +19.0% | 12,973 | +8.0% | 0.69% | +7.0% |
| Q2 2018 | $1,185,000 | -2.5% | 12,012 | -0.8% | 0.64% | -23.8% |
| Q1 2018 | $1,215,000 | +8.4% | 12,112 | +0.3% | 0.85% | +37.9% |
| Q4 2017 | $1,121,000 | +7.5% | 12,077 | +0.2% | 0.61% | +0.3% |
| Q3 2017 | $1,043,000 | +7.7% | 12,055 | +0.9% | 0.61% | +3.2% |
| Q2 2017 | $968,000 | -2.6% | 11,952 | +2.8% | 0.59% | -18.1% |
| Q1 2017 | $994,000 | +11.7% | 11,625 | +1.6% | 0.72% | +1.4% |
| Q4 2016 | $890,000 | -4.0% | 11,440 | -3.3% | 0.71% | -12.4% |
| Q3 2016 | $927,000 | -8.8% | 11,829 | -5.7% | 0.82% | -20.0% |
| Q2 2016 | $1,016,000 | -21.1% | 12,549 | -7.5% | 1.02% | -28.6% |
| Q1 2016 | $1,288,000 | – | 13,573 | – | 1.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |